Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.40 |
| ▸ | TUBB | P07437 | 6/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 6/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106623 | 0.87 | TUBB4A (0.43) | CA1CA2CA12CA9TUBB4A | |
| SCHEMBL6351443 | 0.83 | TUBB4A (0.47) | CA1CA2KRASCA12CA9 | |
| SCHEMBL6346701 | 0.81 | PTGS2 (0.51) | KRASTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6590873 | 0.76 | MEN1 (0.51) | CA1CA2CA12CA9TUBB4A | |
| SCHEMBL7465572 | 0.72 | CA2 (0.47) | CA1CA2KRASCA12CA9 | |
| SCHEMBL154427 | 0.72 | ALDH1A1 (0.51) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11496849 | 0.72 | ALDH1A1 (0.42) | CA1CA2KDM4EMEN1KMT2A | |
| SCHEMBL31330205 | 0.72 | RAPGEF4 (0.47) | CA1CA2KDM4EMEN1KMT2A | |
| SCHEMBL158166 | 0.72 | RAPGEF4 (0.47) | CA1CA2KDM4EMEN1KMT2A | |
| SCHEMBL9307499 | 0.70 | RAPGEF4 (0.46) | CA1CA2CA12CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187246-A1 | Cell proliferation inhibitors | LI QUN (US) | 2005-08-25 | — | — | US | claimed |
| US-20030096856-A1 | Cell proliferation inhibitors | ABBVIE INC. | 2003-05-22 | — | — | US | claimed |
| EP-1181269-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000073264-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2000-12-07 | — | — | WO | claimed |
| US-20050187246-A1 | Cell proliferation inhibitors | LI QUN (US) | 2005-08-25 | — | — | US | disclosed |
| US-6924304-B2 | Cell proliferation inhibitors | ABBOTT LABORATORIES (US) | 2005-08-02 | — | — | US | disclosed |
| US-20030096856-A1 | Cell proliferation inhibitors | ABBVIE INC. | 2003-05-22 | — | — | US | disclosed |
| US-6521658-B1 | Cell proliferation inhibitors | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096856-A1 | Cell proliferation inhibitors | MKI67, CCNI, CCNA1 | CYP19A1 378/4885NQO2 583/4885CA1 2753/4885 |
| US-20050187246-A1 | Cell proliferation inhibitors | MKI67, CCNI, CCNC | CYP19A1 545/4885NQO2 335/4885CA1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.